本公司的電郵信箱於今日起已由 "info@newbinnovation.com" 變更為 "info@newbetainnovation.com"。

本公司的英文名稱已由 "New B Innovation Limited" 變更為 "New Beta Innovation Limited"，自2019 年6 月3 日起生效。此外，公司的中文名稱 "新行健醫藥科技有限公司" 則維持不變。

請知悉是次命名變更是不會影響公司架構以及本公司對外已簽署的合同及協議書。

The First-in-Human (FiH) healthy volunteer study to evaluate safety on the use of YQ23 has commenced on 11 Jan 2019. This study is mainly to assess the safety, tolerability and pharmacokinetics (PK - the amount of study drug in the blood) of ascending single dose of YQ23 in healthy male and female subjects. The clinical trial is conducted at a Phase 1 centre in UK and will enroll approximately 40 subjects.

New Beta Innovation receives approval from the Hong Kong Department of Health (DoH) to proceed with a Phase 1 Clinical Trial (First-in-Patient) of YQ23 in patients with advanced tumors.

YQ23 has been granted the Orphan Medicinal Product Designation by the EMA for the treatment of oesophageal cancer.

New Beta Innovation receives UK Medicines and Healthcare products Regulatory Agency (MHRA) approval to proceed with a Phase 1 Clinical Trial (First-in-Human) of YQ23 in healthy volunteers.

YQ23 has been granted the Orphan Medicinal Product Designation by the EMA for the treatment of hepatocellular carcinoma.